Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Klinikum Rechts Der Isar Der Technischen Universität München has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 2 actions are handled by 2 distinct examiners, which means each examiner is responsible for 1 pending action. This distribution indicates that the institution's current workload is not concentrated under this official. The use of 2 distinct examiners suggests a varied approach to prosecution.
The prosecution is occurring across 2 distinct art units. PERSONS, JENNA L is the busiest examiner with 1 pending action. This 1 pending action is part of the total pending workload for the institution. With 2 distinct art units involved, the applicant must manage separate prosecution tracks simultaneously. Practitioners should ensure consistent arguments are maintained across the examiners and 2 distinct art units to avoid conflicting statements in the Biotechnology & Pharmaceuticals area. These pending office actions reflect the institution's ongoing research in this sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PERSONS, JENNA L | 1 | 50.8% | +61.7% |
| YAMASAKI, ROBERT J | 1 | 67.6% | +43.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17426201 | METHOD FOR DETECTING A SPECIFIC SPLICE EVENT OF A GENE OF INTEREST | PERSONS, JENNA L | 11d overdue |
| 16978048 | TREATMENT OF TUMORS BY A COMBINATION OF AN ONCOLYTIC ADENOVIRUS AND A CDK4/6 INHIBITOR | YAMASAKI, ROBERT J | — |
| Art Unit | Apps |
|---|---|
| 1637 | 1 |
| 1657 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17426201 | METHOD FOR DETECTING A SPECIFIC SPLICE EVENT OF A GENE OF INTEREST | PERSONS, JENNA L | 1637 | §112 | Final Rejection | 11d overdue | Pending | Jul 28, 2021 |
| 16978048 | TREATMENT OF TUMORS BY A COMBINATION OF AN ONCOLYTIC ADENOVIRUS AND A CDK4/6 INHIBITOR | YAMASAKI, ROBERT J | 1657 | §103Other | Final Rejection | — | Pending | Sep 03, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial